D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $20.00 price target on the stock.

Several other brokerages have also recently issued reports on OSTX. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Lake Street Capital dropped their target price on OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.50.

OS Therapies Price Performance

OSTX traded up $0.22 on Monday, reaching $1.79. 1,482,317 shares of the stock were exchanged, compared to its average volume of 584,035. The company’s 50-day moving average price is $1.39 and its 200 day moving average price is $1.75. The firm has a market capitalization of $63.13 million, a PE ratio of -2.18 and a beta of -3.80. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $2.57.

Hedge Funds Weigh In On OS Therapies

Several institutional investors and hedge funds have recently modified their holdings of OSTX. State Street Corp raised its holdings in OS Therapies by 16.3% in the 4th quarter. State Street Corp now owns 58,500 shares of the company’s stock worth $82,000 after purchasing an additional 8,200 shares during the period. Jane Street Group LLC purchased a new stake in shares of OS Therapies in the fourth quarter valued at approximately $39,000. Geode Capital Management LLC raised its stake in shares of OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after buying an additional 58,350 shares during the period. Susquehanna International Group LLP acquired a new position in shares of OS Therapies during the 3rd quarter worth approximately $29,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the 3rd quarter valued at approximately $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.